Alnylam’s $420M Surge Can’t Stop 1.02% Plunge as Trading Activity Ranks 259th

On September 15, 2025, , , ranking 259th in market activity for the day. The biotech firm’s shares saw heightened liquidity amid mixed market sentiment for the sector.

Recent developments suggest investor caution around Alnylam’s therapeutic pipeline. Regulatory updates on its GIVI-112 program for rare diseases triggered volatility, though no new clinical data was disclosed. Analysts noted the stock’s sensitivity to macroeconomic factors, with broader biotech indices showing muted performance as interest rates remain elevated.

To evaluate this strategy rigorously, I need to clarify a few practical details so that I can structure the back-test correctly: 1. Market universe • Do you want all U.S. listed common stocks (NYSE + NASDAQ), or a particular sub-set such as S&P 500 constituents, Russell 3000, etc.? 2. Handling corporate actions & survivorship bias • Should we include delisted stocks (to avoid survivorship bias), or limit the universe to currently listed tickers only? 3. Re-balancing costs • Should we assume zero transaction costs and perfect liquidity, or would you like to impose a fixed bps cost (for example, 2 bp per side) when buying and selling each day? 4. , or weight them by some function of volume (e.g., ? 5. Benchmark (optional) • Would you like the results contrasted with a benchmark index (e.g., SPY)? Once these points are settled, I can automatically generate the full data-retrieval plan, fetch the daily volume ranks, form the daily portfolios, , and deliver the report with interactive visuals.